Sema3C has recently been studied as a novel biomarker in Hepatocellular carcinoma (HCC), where NRP1 and Integrin Beta1 (ITGβ1) act as functional receptors of Sema3C which activates Serine threonine Kinase (AKT)/GLI Family Zinc Finger 1 (Gli1)/c-Myc signaling pathways leading to tumor initiation [91]. The gene discussed is MARK2; the disease is hepatocellular carcinoma.